Insights

Innovative Diagnostic Solutions Biohit offers a range of early diagnosis products for gastrointestinal diseases, providing potential opportunities to partner with healthcare providers and clinics seeking reliable testing solutions for stomach illnesses and colorectal health.

Global Expansion Potential With subsidiaries in China, Italy, and the UK, Biohit is positioned for international growth, opening avenues to distribute and license its diagnostic and biotech products across diverse markets.

Focus on Carcinogen Reduction Biohit's proprietary product Acetium targets the reduction of carcinogenic acetaldehyde in the GI tract, presenting a unique health innovation that can be marketed to health-conscious consumers and preventative healthcare providers.

Social Responsibility Focus The company's commitment to social responsibility and raising awareness about Group I human carcinogens aligns with value-driven health initiatives, creating opportunities for collaborating with public health organizations and educational campaigns.

Growth through Licensing Biohit is actively seeking distributors and licensing partners to expand its product reach, indicating opportunities for sales teams to establish strategic partnerships in both new and existing markets.

Similar companies to Biohit Oyj

Biohit Oyj Tech Stack

Media & News

Biohit Oyj's Email Address Formats

Biohit Oyj uses at least 1 format(s):
Biohit Oyj Email FormatsExamplePercentage
First.Last@biohit.fiJohn.Doe@biohit.fi
95%
Last.First@biohit.fiDoe.John@biohit.fi
2%
FLast@biohit.fiJDoe@biohit.fi
1%
First@biohit.fiJohn@biohit.fi
2%

Frequently Asked Questions

Where is Biohit Oyj's headquarters located?

Minus sign iconPlus sign icon
Biohit Oyj's main headquarters is located at Laippatie 1, Helsinki, Southern Finland 00880, FI. The company has employees across 4 continents, including EuropeAsiaNorth America.

What is Biohit Oyj's official website and social media links?

Minus sign iconPlus sign icon
Biohit Oyj's official website is biohit.fi and has social profiles on LinkedIn.

What is Biohit Oyj's SIC code NAICS code?

Minus sign iconPlus sign icon
Biohit Oyj's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Biohit Oyj have currently?

Minus sign iconPlus sign icon
As of October 2025, Biohit Oyj has approximately 63 employees across 4 continents, including EuropeAsiaNorth America. Key team members include Head Of Diagnostics Department: Y. K.Ceo: J. H.Chairman: O. S.. Explore Biohit Oyj's employee directory with LeadIQ.

What industry does Biohit Oyj belong to?

Minus sign iconPlus sign icon
Biohit Oyj operates in the Biotechnology Research industry.

What is Biohit Oyj's email format?

Minus sign iconPlus sign icon
Biohit Oyj's email format typically follows the pattern of First.Last@biohit.fi. Find more Biohit Oyj email formats with LeadIQ.

When was Biohit Oyj founded?

Minus sign iconPlus sign icon
Biohit Oyj was founded in 1988.
Biohit Oyj

Biohit Oyj

Biotechnology ResearchFinland51-200 Employees

Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit's mission is "Innovating for Health". We are committed to social responsibility and it is our duty to spread knowledge about the Group I human carcinogen, acetaldehyde, and innovate and develop the marketing and availability of our products and services. Biohit is headquartered in Helsinki, Finland and its subsidiaries are located in China, Italy and the United Kingdom. Since 1999, Biohit's series B shares (BIOBV) have been listed in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector. www.biohithealthcare.com

Product range consists of products and analysis systems for the early diagnosis of gastrointestinal diseases, such as the blood-sample based GastroPanel examinations for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and Helicobacter pylori infection in connection with gastroscopy, and the ColonView examination for the early detection of fecal occult intestinal bleeding (faecal occult blood) that indicates a risk of colorectal cancer. Acetium innovation is developed to reduce carcinogenic acetaldehyde in the gastrointestinal tract. We are looking for distributors and licencing partners.

Section iconCompany Overview

Headquarters
Laippatie 1, Helsinki, Southern Finland 00880, FI
Website
biohit.fi
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
1988
Employees
51-200

Section iconMedia & News

Section iconFunding & Financials

  • $100M$250M

    Biohit Oyj's revenue is estimated to be in the range of $100M$250M

Section iconFunding & Financials

  • $100M$250M

    Biohit Oyj's revenue is estimated to be in the range of $100M$250M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.